Skip to content
Parkinson's News Today logo Newsletter
Newsletter
  • About Parkinson's
    What is Parkinson’s disease?
    Causes
    Diagnosis
    Symptoms
    • Motor symptoms
    • Non-motor symptoms
    Living with Parkinson’s
    Types
    Treatments
    • Approved treatments
    • Experimental treatments
    • Non-drug treatments
  • Expert voices
    Integrative medicine
    Deep brain stimulation
    Safe exercise
    Cannabis and Parkinson’s symptoms
    Speech difficulties
    Diet and nutrition
    Caring for mental health
    Managing sex and intimacy issues
  • Parkinson's psychosis guide
    Patients
    • What is psychosis?
    • Talking to your doctor about psychosis
    • Perspective: Living with psychosis
    • Emotional and mental health
    • Psychosis risk factors
    Caregivers of spouses
    • Early signs of psychosis
    • Preparing for psychosis
    • Perspective: Supporting your spouse
    • Respite care
    • Hallucinations, delusions, illusions
    Caregivers of parents
    • Talking to a parent with psychosis
    • Psychosis care options
    • Perspective: Caring for a parent
    • Do’s and don’ts
    • Remote Parkinson’s care
    In focus video series
    • Managing Parkinson’s psychosis
    • Strategies for managing psychosis
    • Early signs of psychosis
    • Discerning Parkinson's-related psychosis
  • News
  • Columns
    The Bright Side – Jamie Askari
    Living My Best Life – Christine Scheer
    The Love Factor – Chukwuemeka Uchebuakor
    PD: The WE Journey – Jill Hammergren
    The Impatient Patient – Doc Irish
    Shaking Things Up — Mary Beth Skylis
    Unshakable Optimist – Mollie Lombardi
    Archived columns
    • Embrace the Shake — Samantha Felder
    • Life, Lemons, and Lemonade — Lori DePorter
    • Possibilities With Parkinson’s — Dr. C
    • Resilient: Living Relentlessly — Jo Gambosi
  • Forums
  • Advocacy partners
  • What can we help you find today?

February 20, 2020 News by Forest Ray PhD

RTB101 Well-tolerated, Crosses Blood-Brain Barrier in Therapeutic Quantities, According to Interim Results

RTB101, an investigational therapy being developed to treat Parkinson’s disease, is well-tolerated, can cross the blood-brain barrier, and reaches potentially therapeutic concentrations in cerebrospinal fluid (CSF), according to interim results of a Phase 1b/2a study. Developed by resTORbio, RTB101 is an orally-administered compound meant…

April 5, 2019 News by Patricia Inácio, PhD

Phase 1/2 Trial to Test Investigational Therapy RTB101 in Parkinson’s Disease

A new Phase 1/2a clinical trial will investigate resTORbio’s therapy candidate RTB101, alone or in combination with sirolimus, as a potential treatment for Parkinson’s disease. Researchers plan to enroll 45 patients with mild Parkinson’s disease, both with and without mutations in the GBA gene, and who are being treated…

Recent Posts

  • Protecting the babies inspires me to move like a ninja
  • PMD Alliance seeking participants for survey on Parkinson’s off time
  • Home care agency receives award for work in Parkinson’s, dementia
  • Gene therapy AAV-GAD wins RMAT designation for Parkinson’s
  • Hillhurst gets $6.3M funding for HBI-002 clinical study


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.